Biophytis S.A. (BPTSY)
OTCMKTS · Delayed Price · Currency is USD
5.37
0.00 (0.00%)
Sep 25, 2024, 4:00 PM EDT

Biophytis Company Description

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases.

Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases.

The company’s lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19.

It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease.

Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD.

The company was incorporated in 2006 and is headquartered in Paris, France.

Biophytis S.A.
Country France
Founded 2006
Industry Biotechnology
Sector Healthcare
Employees 22
CEO Stanislas Veillet

Contact Details

Address:
Sorbonne University
Paris, 75005
France
Phone 33 1 44 27 23 00
Website biophytis.com

Stock Details

Ticker Symbol BPTSY
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency EUR
ISIN Number US09076G4010
SIC Code 2836

Key Executives

Name Position
Stanislas Veillet Ph.D. Chairman of the Board and Chief Executive Officer
Nicolas Fellmann Chief Financial Officer
Waly Dioh Ph.D. Chief Clinical Operating Officer
Dr. Pierre J. Dilda Ph.D. Chief Scientific Officer
Dr. Rene Lafont Scientific Advisor and Member of Scientific Advisory Board
Dr. Rob van Maanen FFPM, M.B.A., M.D. Chief Medical Officer
Edouard Bieth Chief Business Officer
Chiara Baccelli Chief Pharmaceutical Operations Officer and Quality Assurance Director
_ Teylan Financial Controller